{"pmid":32454238,"title":"Management of Venous Thromboembolism During the COVID-19 Pandemic.","text":["Management of Venous Thromboembolism During the COVID-19 Pandemic.","J Vasc Surg Venous Lymphat Disord","Skeik, Nedaa","Mirza, Aleem","Manunga, Jesse","32454238"],"journal":"J Vasc Surg Venous Lymphat Disord","authors":["Skeik, Nedaa","Mirza, Aleem","Manunga, Jesse"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454238","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jvsv.2020.05.005","topics":["Prevention"],"weight":1,"_version_":1667881798460243968,"score":9.490897,"similar":[{"pmid":32474397,"title":"Venous thromboembolism and COVID-19.","text":["Venous thromboembolism and COVID-19.","Respir Med Res","Bertoletti, L","Couturaud, F","Montani, D","Parent, F","Sanchez, O","32474397"],"journal":"Respir Med Res","authors":["Bertoletti, L","Couturaud, F","Montani, D","Parent, F","Sanchez, O"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474397","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.resmer.2020.100759","keywords":["covid-19","coronavirus disease","pulmonary embolism","sars-cov-2","venous thromboembolic disease"],"topics":["Treatment"],"weight":1,"_version_":1668341932680544257,"score":59.355583},{"pmid":32294289,"title":"Venous thromboembolism in COVID-19 patients.","text":["Venous thromboembolism in COVID-19 patients.","We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.","J Thromb Haemost","Porfidia, Angelo","Pola, Roberto","32294289"],"abstract":["We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days."],"journal":"J Thromb Haemost","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294289","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14842","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Enoxaparin","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138494470193152,"score":55.739754},{"pmid":32278361,"pmcid":"PMC7158946","title":"Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19.","text":["Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19.","Lancet Haematol","Wang, Tao","Chen, Ruchong","Liu, Chunli","Liang, Wenhua","Guan, Weijie","Tang, Ruidi","Tang, Chunli","Zhang, Nuofu","Zhong, Nanshan","Li, Shiyue","32278361"],"journal":"Lancet Haematol","authors":["Wang, Tao","Chen, Ruchong","Liu, Chunli","Liang, Wenhua","Guan, Weijie","Tang, Ruidi","Tang, Chunli","Zhang, Nuofu","Zhong, Nanshan","Li, Shiyue"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278361","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/S2352-3026(20)30109-5","topics":["Diagnosis"],"weight":1,"_version_":1666138491567734787,"score":54.05126},{"pmid":32369666,"title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19.","text":["Incidence of venous thromboembolism in hospitalized patients with COVID-19.","Coronavirus disease 2019 (COVID-19) can lead to systemic coagulation activation and thrombotic complications. We investigated the incidence of objectively confirmed venous thromboembolism (VTE) in 198 hospitalized patients with COVID-19 in a single-center cohort study. Seventy-five patients (38%) were admitted to the intensive care unit (ICU). At time of data collection, 16 (8%) were still hospitalized and 19% had died. During a median follow-up of 7 days (IQR, 3-13), 39 patients (20%) were diagnosed with VTE of whom 25 (13%) had symptomatic VTE, despite routine thrombosis prophylaxis. The cumulative incidences of VTE at 7, 14 and 21 days were 16% (95% CI, 10-22), 33% (95% CI, 23-43) and 42% (95% CI 30-54) respectively. For symptomatic VTE, these were 10% (95% CI, 5.8-16), 21% (95% CI, 14-30) and 25% (95% CI 16-36). VTE appeared to be associated with death (adjusted HR, 2.4; 95% CI, 1.02-5.5). The cumulative incidence of VTE was higher in the ICU (26% (95% CI, 17-37), 47% (95% CI, 34-58), and 59% (95% CI, 42-72) at 7, 14 and 21 days) than on the wards (any VTE and symptomatic VTE 5.8% (95% CI, 1.4-15), 9.2% (95% CI, 2.6-21), and 9.2% (2.6-21) at 7, 14, and 21 days). The observed risk for VTE in COVID-19 is high, particularly in ICU patients, which should lead to a high level of clinical suspicion and low threshold for diagnostic imaging for DVT or PE. Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival.","J Thromb Haemost","Middeldorp, Saskia","Coppens, Michiel","van Haaps, Thijs F","Foppen, Merijn","Vlaar, Alexander P","Muller, Marcella C A","Bouman, Catherine C S","Beenen, Ludo F M","Kootte, Ruud S","Heijmans, Jarom","Smits, Loek P","Bonta, Peter I","van Es, Nick","32369666"],"abstract":["Coronavirus disease 2019 (COVID-19) can lead to systemic coagulation activation and thrombotic complications. We investigated the incidence of objectively confirmed venous thromboembolism (VTE) in 198 hospitalized patients with COVID-19 in a single-center cohort study. Seventy-five patients (38%) were admitted to the intensive care unit (ICU). At time of data collection, 16 (8%) were still hospitalized and 19% had died. During a median follow-up of 7 days (IQR, 3-13), 39 patients (20%) were diagnosed with VTE of whom 25 (13%) had symptomatic VTE, despite routine thrombosis prophylaxis. The cumulative incidences of VTE at 7, 14 and 21 days were 16% (95% CI, 10-22), 33% (95% CI, 23-43) and 42% (95% CI 30-54) respectively. For symptomatic VTE, these were 10% (95% CI, 5.8-16), 21% (95% CI, 14-30) and 25% (95% CI 16-36). VTE appeared to be associated with death (adjusted HR, 2.4; 95% CI, 1.02-5.5). The cumulative incidence of VTE was higher in the ICU (26% (95% CI, 17-37), 47% (95% CI, 34-58), and 59% (95% CI, 42-72) at 7, 14 and 21 days) than on the wards (any VTE and symptomatic VTE 5.8% (95% CI, 1.4-15), 9.2% (95% CI, 2.6-21), and 9.2% (2.6-21) at 7, 14, and 21 days). The observed risk for VTE in COVID-19 is high, particularly in ICU patients, which should lead to a high level of clinical suspicion and low threshold for diagnostic imaging for DVT or PE. Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival."],"journal":"J Thromb Haemost","authors":["Middeldorp, Saskia","Coppens, Michiel","van Haaps, Thijs F","Foppen, Merijn","Vlaar, Alexander P","Muller, Marcella C A","Bouman, Catherine C S","Beenen, Ludo F M","Kootte, Ruud S","Heijmans, Jarom","Smits, Loek P","Bonta, Peter I","van Es, Nick"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369666","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14888","locations":["optimal"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496266403840,"score":49.68618},{"pmid":32396903,"title":"Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?","text":["Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?","Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Therefore, it is reasonable to assume a high incidence of VTE among these patients. Presently, the incidence of VTE is estimated at around 25% of patients hospitalized in the intensive care unit for COVID-19 even under anticoagulant treatment at prophylactic doses. In this review, we discuss present knowledge of the topic, the unique challenges of diagnosis and treatment of VTE, as well as some of the potential mechanisms of increased risk for VTE during the illness. Understanding the true impact of VTE on patients with COVID-19 will potentially improve our ability to reach a timely diagnosis and initiate proper treatment, mitigating the risk for this susceptible population during a complicated disease.","Acta Haematol","Tal, Shir","Spectre, Galia","Kornowski, Ran","Perl, Leor","32396903"],"abstract":["Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Therefore, it is reasonable to assume a high incidence of VTE among these patients. Presently, the incidence of VTE is estimated at around 25% of patients hospitalized in the intensive care unit for COVID-19 even under anticoagulant treatment at prophylactic doses. In this review, we discuss present knowledge of the topic, the unique challenges of diagnosis and treatment of VTE, as well as some of the potential mechanisms of increased risk for VTE during the illness. Understanding the true impact of VTE on patients with COVID-19 will potentially improve our ability to reach a timely diagnosis and initiate proper treatment, mitigating the risk for this susceptible population during a complicated disease."],"journal":"Acta Haematol","authors":["Tal, Shir","Spectre, Galia","Kornowski, Ran","Perl, Leor"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396903","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1159/000508233","keywords":["covid-19","deep vein thrombosis","pulmonary emboli","venous thromboembolism"],"topics":["Treatment"],"weight":1,"_version_":1666627827809648640,"score":49.68618}]}